EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†.
暂无分享,去创建一个
W. Oyen | M. Babjuk | S. Culine | A. Horwich | V. Khoo | N. Agarwal | J. Witjes | P. Wiklund | A. Kiltie | B. Bochner | M. Remzi | S. Fanti | E. Compérat | T. Wiegel | A. Briganti | S. Shariat | M. Bolla | B. Tombal | T. Reijke | J. Futterer | A. Hartmann | B. Turkbey | N. James | K. Decaestecker | V. Fonteyne | J. Rosenberg | O. Rouvière | M. Frydenberg | P. Hoskin | K. Herrmann | M. Santis | C. Salembier | J. Bellmunt | D. Hansel | P. Lara | H. V. Van Poppel | A. Kamat | R. Zigeuner | A. Chiti | A. Henry | M. Rouprêt | H. Pappot | A. Necchi | P. Black | S. Crabb | H. Mostafid | R. Meijer | J. Boormans | S. Ladoire | P. Gontero* | T. Powles | A. Stenzl | Y. Loriot | F. Roghmann | M. Retz | D. Castellano | M. Moschini | R. Cathomas | G. Gakis | A. G. van der Heijden | A. Choudhury | S. Hafeez | Y. Neuzillet | T. Kwast | R. Valdagni | B. Jereczek-Fossa | E. Xylinas | G. Thalmann | J. Richenberg | V. Løgager | P. D. De Visschere | H. Herr | S. Maclennan | K. Plass | M. Ribal | J. N'Dow | S. Gillessen | R. Jones | Dickon Hayne | A. Bossi | A. Sherif | J. Oddens | A. Bamias | B. Pieters | S. Osanto | A. Birtle | H. M. Bruins | V. Hernández | E. Veskimäe | A. Vilaseca | A. Müller | R. Smeenk | B. Geavlete | S. Sengupta | J. Oldenburg | J. Huguet | J. Palou | S. Krege | M. I. Patel | A. Lorch | J. Dominguez-escrig | P. Sargos | K. Dimitropoulos | M. Vartolomei | M. Mir | M. Burger | E. Linares-Espinós | T. Arends | B. Grubmüller | M. Rink | B. Bari | S. V. Lauridsen | I. Brummelhuis | L. Pacheco-Figueiredo | W. D. Blok | A. Salminen | A. Leliveld | C. Müller | A. Smits | A. Williams | F. A. V. Rivera | P. Gontero
[1] G. De Velasco,et al. SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018) , 2018, Clinical and Translational Oncology.
[2] R. Weichselbaum. The 46th David A. Karnofsky Memorial Award Lecture: Oligometastasis-From Conception to Treatment. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[4] R. Adam,et al. Immunology, Immunotherapy, and Translating Basic Science into the Clinic for Bladder Cancer , 2018, Bladder cancer.
[5] E. B. Butler,et al. The Role of Adjuvant Radiation Therapy in Locally Advanced Bladder Cancer , 2018, Bladder cancer.
[6] Xiaokun Zhao,et al. Pretreatment Neutrophil-Lymphocyte Ratio as a Predictor in Bladder Cancer and Metastatic or Unresectable Urothelial Carcinoma Patients: a Pooled Analysis of Comparative Studies , 2018, Cellular Physiology and Biochemistry.
[7] P. Hegde,et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial , 2018, The Lancet.
[8] M. Höglund,et al. A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort , 2018, Scientific Reports.
[9] T. Powles,et al. Response Rate to Chemotherapy After Immune Checkpoint Inhibition in Metastatic Urothelial Cancer. , 2018, European urology.
[10] R. Bourgon,et al. TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells , 2018, Nature.
[11] M. Leech,et al. A review of plan library approaches in adaptive radiotherapy of bladder cancer , 2018, Acta oncologica.
[12] A. Zlotta,et al. The Role of Surgery in Metastatic Bladder Cancer: A Systematic Review. , 2017, European urology.
[13] M. Babjuk,et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update. , 2015, European urology.
[14] M. Menon,et al. Neoadjuvant chemotherapy prior to radical cystectomy for muscle‐invasive bladder cancer with variant histology , 2017, Cancer.
[15] T. Powles,et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. , 2017, The Lancet. Oncology.
[16] Steven J. M. Jones,et al. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer , 2017, Cell.
[17] T. Powles,et al. Immune Checkpoint Inhibition in Metastatic Urothelial Cancer. , 2017, European urology.
[18] K. Hoadley,et al. Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. , 2017, European urology.
[19] P. Choyke,et al. Advances in medical imaging for the diagnosis and management of common genitourinary cancers. , 2017, Urologic oncology.
[20] A. Giobbie-Hurder,et al. Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions , 2017, Clinical Cancer Research.
[21] A. Niemierko,et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. , 2017, European urology.
[22] M. Menon,et al. NEOADJUVANT CHEMOTHERAPY PRIOR TO RADICAL CYSTECTOMY FOR MUSCLE‐INVASIVE BLADDER CANCER WITH VARIANT HISTOLOGY: MP34‐11 , 2017 .
[23] S. Culine,et al. Pembrolizumab as Second‐Line Therapy for Advanced Urothelial Carcinoma , 2017, The New England journal of medicine.
[24] R. Bourgon,et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial , 2017, The Lancet.
[25] W. Hwang,et al. Neutrophil‐to‐lymphocyte ratio as a bladder cancer biomarker: Assessing prognostic and predictive value in SWOG 8710 , 2016, Cancer.
[26] Jacques Ferlay,et al. Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. , 2017, European urology.
[27] E. Gallardo,et al. SEOM Clinical Guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2016) , 2016, Clinical and Translational Oncology.
[28] Haitao Niu,et al. Prognostic Role of Lactate Dehydrogenase Expression in Urologic Cancers: A Systematic Review and Meta-Analysis , 2016, Oncology Research and Treatment.
[29] Holger Moch,et al. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. , 2016, European urology.
[30] R. Bourgon,et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial , 2016, The Lancet.
[31] D. Tilki,et al. Urethral recurrence after cystectomy: current preventative measures, diagnosis and management , 2016, BJU international.
[32] G. Pond,et al. Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma. , 2016, The Journal of urology.
[33] T. Eade,et al. Promising results with image guided intensity modulated radiotherapy for muscle invasive bladder cancer , 2015, Radiation Oncology.
[34] Jin-Hee Ahn,et al. Pulmonary Metastasectomy Could Prolong Overall Survival in Select Cases of Metastatic Urinary Tract Cancer. , 2015, Clinical genitourinary cancer.
[35] C. Pollack,et al. Collaboration Between Surgeons and Medical Oncologists and Outcomes for Patients With Stage III Colon Cancer. , 2015, Journal of oncology practice.
[36] B. Czerniak,et al. Clinical outcomes of cT1 micropapillary bladder cancer. , 2015, The Journal of urology.
[37] M. Mcintyre,et al. Exploration of the role of specialist nurses in the care of women with gynaecological cancer: a systematic review. , 2015, Journal of clinical nursing.
[38] Liang Cheng,et al. Contemporary bladder cancer: variant histology may be a significant driver of disease. , 2015, Urologic oncology.
[39] Steven L. Chang,et al. Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. , 2014, European urology.
[40] C. Rasch,et al. Bladder preservation with brachytherapy compared to cystectomy for T1-T3 muscle-invasive bladder cancer: a systematic review , 2014, Journal of contemporary brachytherapy.
[41] J. Witjes,et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. , 2014, European urology.
[42] Katherine A. Hoadley,et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology , 2014, Proceedings of the National Academy of Sciences.
[43] K. Baggerly,et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. , 2014, Cancer cell.
[44] A. Horwich,et al. Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[45] G. Sonpavde,et al. Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin‐based chemotherapy , 2013, Cancer.
[46] J. Huguet. Seguimiento oncológico después de cistectomía radical basado en patrones de recidiva tumoral y sus factores de riesgo , 2013 .
[47] J. Huguet. Follow-up after radical cystectomy based on patterns of tumor recurrence and its risk factors , 2013 .
[48] M. Babjuk,et al. Guidelines on Non-muscle invasive Bladder Cancer , 2013 .
[49] Ji-An Liang,et al. Clinical value of FDG PET or PET/CT in urinary bladder cancer: a systemic review and meta-analysis. , 2012, European journal of radiology.
[50] Emma Hall,et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. , 2012, The New England journal of medicine.
[51] A. Qayyum,et al. Clinical Investigation : Genitourinary Cancer Whole-Pelvis or Bladder-Only Chemoradiation for Lymph Node e Negative Invasive Bladder Cancer : Single-Institution Experience , 2012 .
[52] R. Cowan,et al. Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] H. Samaratunga,et al. Micropapillary urothelial carcinoma of the urinary bladder: a clinicopathological analysis of 72 cases , 2010, Pathology.
[54] P. Hoskin,et al. Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[55] T. Kessler,et al. Do patients benefit from routine follow-up to detect recurrences after radical cystectomy and ileal orthotopic bladder substitution? , 2010, European urology.
[56] Mattias Höglund,et al. Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. , 2010, Cancer research.
[57] S. Culine,et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] Cary Siegel,et al. Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[59] R. Shah,et al. Multiple adverse histological features increase the odds of under staging T1 bladder cancer. , 2009, The Journal of urology.
[60] K. Kihara,et al. Favourable outcomes of patients with clinical stage T3N0M0 bladder cancer treated with induction low‐dose chemo‐radiotherapy plus partial or radical cystectomy vs immediate radical cystectomy: a single‐institutional retrospective comparative study , 2009, BJU international.
[61] P. Albers,et al. Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05). , 2009, European urology.
[62] R. Kuefer,et al. Oncological followup after radical cystectomy for bladder cancer-is there any benefit? , 2009, The Journal of urology.
[63] Gerhard Jakse,et al. The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. , 2009, European urology.
[64] C. Dinney,et al. The impact of variant histology on the outcome of bladder cancer treated with curative intent. , 2009, Urologic oncology.
[65] H. G. van der Poel,et al. Urinary diversions after cystectomy: the association of clinical factors, complications and functional results of four different diversions. , 2008, European urology.
[66] G. Bepler,et al. Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[67] N. Shinohara,et al. Impact of multimodal treatment on survival in patients with metastatic urothelial cancer. , 2007, European urology.
[68] S. Ricci,et al. Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer , 2005 .
[69] Federación de Sociedades Españolas de Oncología. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. , 2005 .
[70] N. Masumori,et al. Local recurrence after radical cystectomy for invasive bladder cancer: an analysis of predictive factors. , 2004, Urology.
[71] A. Rosales,et al. Management and prognosis of transitional cell carcinoma superficial recurrence in muscle-invasive bladder cancer after bladder preservation. , 2003, European urology.
[72] M. Mazumdar,et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[73] M Buyse,et al. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. , 1997, The Journal of thoracic and cardiovascular surgery.
[74] I. Tannock,et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[75] H. Awwad,et al. Postoperative radiotherapy of carcinoma in bilharzial bladder: improved disease free survival through improving local control. , 1992, International journal of radiation oncology, biology, physics.
[76] J. Garland. The New England Journal of Medicine. , 1961, Canadian Medical Association journal.